Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXT608 in healthy adults
NCT05408663Phase 1Completed
- Sponsor
- Extend Biosciences
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypoparathyroidism comparing EXT608 with Placebo (2 arms). Primary endpoint: Safety and Tolerability of EXT608. Started Jul 2022; status: completed.
02
Drugs
ext608
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT05408663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408663.